ライフサイエンスコーパス: EIA

1 EIA determined leukotriene B4, and ELISAs quantified TNF

2 EIA produced disruptions in social behavior and increase

3 EIA stenoses were significantly longer in women (P < .00

4 Upon hip flexion, 23 CIA and 116 EIA stenoses showed kinking (mean amplitude, 76 degrees

5 red testing (MTTT) algorithms, including a 2-EIA algorithm and modified criteria for second-tier IgG

6 e data add to the mounting evidence that a 2-EIA-based MTTT algorithm, where immunoblotting is replac

7 The 2-EIA MTTT algorithm slightly enhanced sensitivity in earl

8 In addition, the MTTT algorithm utilizing 2-EIAs was found to be equivalent to all STTT algorithms t

9 the 1996 group as compared to 34.3% in 2011 (EIA, P < 0.001).

10 y mortality was 13% in 2222 adults with 2745 EIA-positive samples (median, 78 years) vs 5% in 20,722

11 78 years) vs 5% in 20,722 adults with 27,550 EIA-negative samples (median, 74 years) (absolute attrib

12 Most (71.6%) EIA-positive samples were positive by PCR for C. jejuni/

13 d CIN3+ was assessed relative to the GP5+/6+ EIA results by using noninferiority criteria.

14 calcitonin (PCT) was &0.25 ng/ml in 52 (83%) EIA+ patients, suggesting infection was not bacterial.

15 tion of RT (Orasure) vs LBT (HIV Combo Ag/Ab EIA, HCV EIA) for HIV and HCV at a drug detoxification c

16 n of electromagnetically induced absorption (EIA) through near-field coupling in these systems has on

17 ects of early-life immune system activation (EIA)-comprising regimens of prenatal, early postnatal, o

18 denovirus promoter and suppresses adenovirus EIA gene expression, which is a master regulator of aden

19 from the Energy Information Administration (EIA) was combined with data from the Environmental Prote

20 in the US Energy Information Administration (EIA)'s Annual Energy Outlook (AEO), for investment and p

21 The highly specific and sensitive HCV-Ags EIA developed in the present study has the lowest limit

22 ondenaturation of serum samples, our HCV-Ags EIA reliably differentiated V-HCV infection from resolve

23 d, using sample nondenaturation, the HCV-Ags EIA results showed 98.9% specificity and 100% sensitivit

24 HCV infection and developed a novel HCV-Ags EIA through simultaneous detection of all four HCV prote

25 he lowest limits of detection of the HCV-Ags EIA were equivalent to serum HCV RNA levels of approxima

26 vel HCV antigens enzyme immunoassay (HCV-Ags EIA) and assessed its sensitivity, specificity, and util

27 The high proportion of SRA positivity among EIA-seroconverting patients (8/11 [73%]) suggests that p

28 bacter jejuni, and Campylobacter coli and an EIA for Shiga toxins 1 and 2.

29 Verification studies of an EIA compared to culture revealed a positive predictive v

30 Given that the primary purpose of an EIA is to make planning decisions evidence-based, our re

31 Combining antigen and EIA antibody testing provides an optimal method for diag

32 They were mild (CIA and EIA mean severity, 19% +/- 7 and 26% +/- 11, respectivel

33 CIA and EIA stenoses predominantly involved the distal and proxi

34 ere identified by both SMAC agar culture and EIA, 6 (9%) by SMAC agar culture alone, and 2 (3%) by EI

35 Based on these data, culture and EIA-based methods for detection of STEC are only 33% sen

36 IIA and EIA are 2 well-established techniques for restoration of

37 The LMNX and EIA were in high agreement (Cohen's kappa = 0.969) for t

38 small heterodimer partner (SHP, NR0B2), and EIA-like inhibitor of differentiation 1 (EID1) in choles

39 compared with cases detected by both PCR and EIA/CCA (3% vs 39%, respectively; P < .001).

40 The incidence rate ratio comparing PCR and EIA/CCA was 1.52 (95% CI, 1.08-2.13; P = .015).

41 om different clades/sequence types (STs) and EIA-negative controls using Cox and normal regression ad

42 Both NAb titers and EIA detectable Abs are increased in patients experiencin

43 The MVista Histoplasma antibody EIA offers increased sensitivity over current antibody t

44 controls in the MVista Histoplasma antibody EIA.

45 noassay and cell culture cytotoxicity assay (EIA/CCA).

46 ch required Environmental Impact Assessment (EIA) for certain types of industrial and infrastructure

47 Environmental Impact Assessments (EIAs) are the main tool used across the world to predict

48 A new VRD B19V IgG avidity EIA showed good (>95%) agreement (excluding equivocal re

49 The concordance between EIA and IFA findings was 96.7%.

50 %) by SMAC agar culture alone, and 2 (3%) by EIA alone.

51 per 10 000 patient-days (95% CI, 4.4-7.4) by EIA/CCA (P = .01).

52 CDI was diagnosed by PCR and 39% (22/56) by EIA/CCA (P = .16).

53 C1-INH functional activity was assessed by EIA.

54 Detection of stool toxin A and/or B by EIA does not predict severe CDI or mortality.

55 gnosed by positive testing for toxins A/B by EIA or PCR for the tcdB gene, we quantified stool toxin

56 I cases were detected by PCR and 56 cases by EIA/CCA (P = .01).

57 199 samples were diagnosed by EIA and 447 were diagnosed by PCR.

58 The presence of stool toxin measured by EIA does not correlate with disease severity.

59 orally inoculated aged pig were positive by EIA, IHC, and/or WB.

60 gative-continue to test strongly positive by EIA-IgG.

61 associated specimens were toxin positive by EIA.

62 Toxin positivity by EIA and CCA associated with IDSA severity, but not with

63 t react with hMPV IgG-positive human sera by EIA.

64 We performed a C6 EIA on all collected specimens, followed by a supplement

65 th both a whole-cell sonicate (WCS) and a C6 EIA, with a supplemental immunoblot if either EIA was po

66 ence, expressed (VlsE) CLIA followed by a C6 EIA.

67 approach where the second-tier test was a C6 EIA.

68 ole-cell sonicate (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a VlsE chemiluminescence

69 immunoblot) to MTTT (WCS EIA followed by C6 EIA) using McNemar's test to evaluate for agreement beyo

70 We then compared the performance of the C6 EIA alone and as a first-tier test followed by immunoblo

71 The C6 EIA alone had sensitivity similar to that of standard 2-

72 dergoing evaluation for Lyme disease, the C6 EIA could guide initial clinical decision making, althou

73 However, the C6 EIA has not been extensively studied in pediatric patien

74 lowed by a supplemental immunoblot if the C6 EIA result was positive but the whole-cell sonicate EIA

75 mmunoblot improved the specificity of the C6 EIA to 98.6%.

76 , where immunoblotting is replaced by the C6 EIA, performs as well or better than STTT.

77 In this study, an IgG antibody capture EIA was developed and validated to detect anti-HTLV-1/2

78 We conclude that the developed Chip EIA can be used for detection of protein biomarkers in b

79 A power-free, portable "Chip EIA" was designed to render the popular Enzyme Linked Im

80 The lower detection limit of the PSA Chip EIA was 3.2 ng/mL.

81 The PSA Chip EIA was tested for accuracy, precision, repeatability, a

82 The Chip EIA device was used to assay total prostate specific ant

83 The Chip EIA platform has eliminated the need for pumps and valve

84 CIA, EIA, and femoral lesions were not randomly associated (P

85 The CIA, EIA, and femoral lesion classification may help to disti

86 We compared culture for C. jejuni/C. coli, EIA (ProSpecT), and duplex PCR to distinguish Campylobac

87 By competition EIA, no cross-reactivity between the BuVs was detected,

88 were evaluated, including stool EIA, culture EIA, and real-time PCR (tcdA and tcdB) of cultured isola

89 tivity superior to that of stool and culture EIAs and performance comparable to that of real-time PCR

90 microbiological methods, including culture, EIA, and reverse-transcriptase PCR.

91 The GP5+/6+-PCR EIA (EIA) was used as a comparator assay and showed sensitivi

92 IA, with a supplemental immunoblot if either EIA was positive or equivocal.

93 V-specific IgG and IgM, IgG avidity, and ETS EIAs.

94 19.25%) O&P examinations, 47/204 (23.04%) GC-EIA, and 249/1,229 (20.26%) STCUL were ordered after 3 d

95 (8.83%) O&P examinations, 27/157 (17.20%) GC-EIA, and 106/1,028 (10.31%) STCUL were ordered after 3 d

96 O&P examinations (P < 0.0001), 22.58% for GC-EIA (P = 0.2807), and 49.1% for STCUL (P < 0.0001).

97 yptosporidium enzyme immunoassay screens (GC-EIA) performed for patients hospitalized >3 days.

98 C. difficile status was assessed by GDH EIA and real-time PCR targeting the toxin A (tcdA) and B

99 One MAb had broad cross-genogroup EIA reactivity to a nonblockade, linear, conserved epito

100 HBV antibodies and GM-EIA positivity are common in patients receiving IVIG and

101 Qualitative agreement between LFA and GM-EIA was 89.0%, generating a Kappa statistic of 0.698, re

102 ce with the Bio-Rad Aspergillus Ag assay (GM-EIA) was performed.

103 rm in the following three stages: (i) DS2 GM-EIA method validation with experimental samples, (ii) DS

104 amples, and (iii) a 12-month audit of DS2 GM-EIA performance.

105 a reduction in false-positive (equivocal) GM-EIA results, reducing the need to retest a significant p

106 rapid alternative to the well-established GM-EIA, potentially detecting more GM epitopes and enhancin

107 Certain IVIG products tested positive for GM-EIA and there were rises in index values in correspondin

108 samples post-infusion tested positive for GM-EIA.

109 sion of galactomannan enzyme immunoassay (GM-EIA) (2002) and beta-d-glucan (2008), providing a minima

110 The galactomannan enzyme immunoassay (GM-EIA) is widely utilized for the diagnosis of invasive as

111 nces in galactomannan enzyme immunoassay (GM-EIA) performance have been reported and are attributed t

112 ies and galactomannan enzyme immunoassay (GM-EIA) positivity.

113 bserved sample agreement between the IMMY GM-EIA and Bio-Rad GM-EIA was 94.7%, generating a kappa sta

114 The median GMIs generated by the IMMY GM-EIA for samples originating from probable IA/IFD cases (

115 I positivity threshold of >=0.5, the IMMY GM-EIA had a sensitivity and specificity of 71% and 98%, re

116 The IMMY GM-EIA provides a comparable alternative to the Bio-Rad GM-

117 The IMMY GM-EIA was performed following the manufacturer's instructi

118 us galactomannan enzyme immunoassay (IMMY GM-EIA) when testing serum samples and to identify the opti

119 least equivalent to that used to include GM-EIA and beta-d-glucan testing, and that PCR is now matur

120 When incorporated, GM-EIA and beta-d-glucan sensitivities and specificities fo

121 discordance arising due to false-negative GM-EIA samples that were positive by LFA.

122 ); and pre- and post-infusion analysis of GM-EIA in 37 patients receiving IVIG.

123 ing therapy such as rituximab; a positive GM-EIA result prompts investigation or treatment for invasi

124 d were comparable to those of the Bio-Rad GM-EIA (0.70, 0.04, and 0.04, respectively).

125 ement between the IMMY GM-EIA and Bio-Rad GM-EIA was 94.7%, generating a kappa statistic of 0.820.

126 s a comparable alternative to the Bio-Rad GM-EIA when testing serum samples.

127 the Bio-Rad Aspergillus Ag assay (Bio Rad GM-EIA) and IMMY sona Aspergillus lateral flow assay was as

128 This study demonstrates that GM-EIA automation may reduce intersite variability.

129 dy investigated the semiautomation of the GM-EIA on the DS2 (Dynex) platform in the following three s

130 cantly greater than that generated by the GM-EIA.

131 T (Orasure) vs LBT (HIV Combo Ag/Ab EIA, HCV EIA) for HIV and HCV at a drug detoxification center.

132 We detected, by in-house EIA, BuV1-3 IgG antibodies in 7/228 children (3.1%) and

133 omosis (IIA) and LRC with extracorporeal IA (EIA).

134 EIA to 98.4% (96.1 to 99.4) for the Trep-ID EIA.

135 9V IgM positive by a commercial VRD B19V IgM EIA and B19V IgM negative by a new HI in-house B19V VP2

136 Both VRD B19V qPCR and HI B19V VP2 IgM EIA gave the highest agreement with consensus interpreta

137 M negative by a new HI in-house B19V VP2 IgM EIA.

138 s of the common iliac (CIA), external iliac (EIA), and femoral arteries were classified into five typ

139 sted for Shiga toxins by enzyme immunoassay (EIA) (ImmunoCard STAT! enterohemorrhagic E. coli [EHEC];

140 We compared paired enzyme immunoassay (EIA) and latex agglutination (LA) assay results with 185

141 their antigenicities by enzyme immunoassay (EIA) and surrogate antibody neutralization (blockade) as

142 sly with the GP5+/6+ PCR enzyme immunoassay (EIA) and the GP5+/6+ PCR LMNX assay (Diassay) were teste

143 or C. difficile by toxin enzyme immunoassay (EIA) and toxigenic culture (TC).

144 (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse outcomes than those

145 for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomav

146 se includes a first-tier enzyme immunoassay (EIA) followed by a supplemental immunoblot, and modified

147 or Lyme disease (LD), an enzyme immunoassay (EIA) followed by immunoglobulin M and immunoglobulin G W

148 istep algorithm using an enzyme immunoassay (EIA) for detection of glutamate dehydrogenase (GDH) and

149 key (SMAC) agar culture, enzyme immunoassay (EIA) for Shiga toxin, or the simultaneous use of both me

150 Enzyme immunoassay (EIA) for toxins A/B is too insensitive for use as a stan

151 cially-available C6 Lyme enzyme immunoassay (EIA) has been approved to replace the standard whole-cel

152 Antibody detection by enzyme immunoassay (EIA) may increase sensitivity and permit the measurement

153 for toxins A and/or B by enzyme immunoassay (EIA) or tcdB by polymerase chain reaction.

154 ter antigen detection by enzyme immunoassay (EIA) provides rapid results compared to traditional cult

155 tions of a Campylobacter enzyme immunoassay (EIA) result and the increasing importance of molecular t

156 m routine culture and an enzyme immunoassay (EIA) specific for the recovery and identification of STE

157 ctive Treponema pallidum enzyme immunoassay (EIA) tests.

158 nd a competitive magneto-enzyme immunoassay (EIA) that enables high sensitivity.

159 rst tier is typically an enzyme immunoassay (EIA) that if positive or equivocal is reflexed to Wester

160 unofluorescence assay or enzyme immunoassay (EIA) that, if the result is positive or equivocal, is fo

161 The addition of toxin enzyme immunoassay (EIA) to nucleic acid amplification tests, including PCR,

162 ibodies were measured by enzyme immunoassay (EIA) with confirmation by immunofluorescence or recombin

163 xiom Diagnostics HEV IgG enzyme immunoassay (EIA), and the Mikrogen recomLine HEV IgG assay.

164 n (GM) in urine using an enzyme immunoassay (EIA), and we showed low positive agreement (64.5%) with

165 in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags.

166 ologic tests, such as an enzyme immunoassay (EIA), followed by Western blot testing, to diagnose extr

167 ng (WB), antigen capture enzyme immunoassay (EIA), immunohistochemistry (IHC), and in vitro real-time

168 ted in stool by culture, enzyme immunoassay (EIA), or PCR.

169 PF4/heparin IgG-specific enzyme immunoassay (EIA), testing serial serum samples in a patient with rec

170 xin antigen detection by enzyme immunoassay (EIA), toxigenic culture, and fecal calprotectin were per

171 stridium difficile toxin enzyme immunoassay (EIA)-positive fecal samples from Oxfordshire, United Kin

172 test (SCT), the GP5+/6+ enzyme immunoassay (EIA).

173 body to hRSV and hMPV by enzyme immunoassay (EIA).

174 e verified by a standard enzyme immunoassay (EIA).

175 sted for EBV antibody by enzyme immunoassay (EIA).

176 rus Iowa-G/USA-06 and by enzyme immunoassay (EIA).

177 antigen testing with an enzyme immunoassay (EIA).

178 rformed using an HEV IgG enzyme immunoassay (EIA, Axiom Diagnostics), and the recomLine HEV IgG immun

179 assays including enzyme-linked immunoassay (EIA), complement fixation (CF) and immunodiffusion (IMDF

180 telia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM).

181 iscordant results (e.g., enzyme immunoassay [EIA] reactive and reactive plasma reagin [RPR] nonreacti

182 PPA); and (7) Trep-Sure (enzyme immunoassay [EIA]), using a reference standard combining clinical dia

183 -release assay [SRA] and enzyme-immunoassay [EIA]), and the frequency of recurrent HIT in 20 patients

184 ransitioning from toxin enzyme immunoassays (EIA) to nucleic acid amplification tests (NAATs) as the

185 omparator method; toxin enzyme immunoassays (EIA), glutamate dehydrogenase (GDH) detection, and PCR w

186 Currently, culture and enzyme immunoassays (EIAs) are the primary methods used by clinical laborator

187 type specificity (ETS) enzyme immunoassays (EIAs) for distinguishing past from recent infection.

188 pically performed using enzyme immunoassays (EIAs), is invasive, sometimes socially unacceptable, and

189 ers, viral Ag binding Abs were detectable in EIA tests.

190 espectively, vs 7.0 x 10(9) neutrophils/L in EIA-negative controls (P < .0001) and 7.9 x 10(9) neutro

191 ents with a positive TC but a negative index EIA developed CDI within 30 days after the index test or

192 Intraoperative heparin induced EIA seroconversion in 11/17 (65%) patients (immunoglobul

193 he Bio-Rad WB (0.90); within 60 days, the LS-EIA and BED (both 0.85); and for persons within 90 days

194 Overall, the LYM/LYG EIAs performed equivalently to the LYT EIA in test-to-te

195 The dissociated LYM/LYG EIAs were evaluated against the combined LYT EIA using s

196 the Vidas Lyme IgM II (LYM) and IgG II (LYG) EIAs, which use purified recombinant test antigens and a

197 EIAs were evaluated against the combined LYT EIA using samples from 471 well-characterized Lyme patie

198 M/LYG EIAs performed equivalently to the LYT EIA in test-to-test comparisons or as first-tier assays

199 tive IMMY GM ASR results and positive MVista EIA results, testing was performed for initial diagnosti

200 The MVista EIA results were positive for 6/12 samples that tested i

201 es for one patient (<0.4 ng/ml by the MVista EIA) and UAg levels were being monitored for the remaini

202 g two patients (both<0.7 ng/ml by the MVista EIA).

203 (135/150 samples) with respect to the MVista EIA.

204 es were tested with both the IMMY and MVista EIAs, and clinical histories were recorded for all study

205 A classical analog of EIA opens up opportunities for designing novel photonic

206 Performing PCR instead of EIA/CCA is associated with a >50% increase in the CDI in

207 , respectively, compared with the results of EIA and 8.7% and 98.0%, respectively, compared with the

208 associated with an increased sensitivity of EIA (P = 0.31).

209 In a subset of EIA+/VDRL-/TP-PA+ cases, 48% were previously treated.

210 diagnosis, LFA identified nearly a third of EIA+ infections.

211 Automation of EIAs can reduce variation.

212 e (HI), Helsinki, Finland, using a number of EIAs, e.g., B19V-specific IgG and IgM, IgG avidity, and

213 ation of qPCR or by appropriate selection of EIAs.

214 >1 assay, are more expensive than the older EIA assays; however, rapid and accurate testing can save

215 Compared to culture or EIA, the positive percent agreement (PPA) and negative p

216 Serum analysis using an oxytocin EIA kit indicated a significant up-regulation of the bio

217 ve value were 56%, 100%, 100%, and 90% for P-EIA and 81%, 100%, 100%, and 96% for both algorithm 1 an

218 ifficile toxin A and B enzyme immunoassay [P-EIA]).

219 ions with superior sensitivity compared to P-EIA.

220 The GP5+/6+-PCR EIA (EIA) was used as a comparator assay and showed sens

221 eceived complete treatment to all 112 PCR(+)/EIA(+) patients showed no differences in CDI-related com

222 For 67 PCR(+)/EIA(-) patients who did not receive complete treatment,

223 d a retrospective cohort study on all PCR(+)/EIA(-) adult inpatients and assessed CDI-related complic

224 CDI-attributable complications among PCR(+)/EIA(-) patients include baseline severe disease by IDSA

225 ns (11% and 13% for PCR(+)/EIA(-) and PCR(+)/EIA(+) patients, respectively), 60-day all-cause mortali

226 ty (17% and 18% for PCR(+)/EIA(-) and PCR(+)/EIA(+) patients, respectively), or recurrent CDI (7% and

227 CDI (7% and 9% for PCR(+)/EIA(-) and PCR(+)/EIA(+) patients, respectively).

228 elated complications (11% and 13% for PCR(+)/EIA(-) and PCR(+)/EIA(+) patients, respectively), 60-day

229 all-cause mortality (17% and 18% for PCR(+)/EIA(-) and PCR(+)/EIA(+) patients, respectively), or rec

230 ely), or recurrent CDI (7% and 9% for PCR(+)/EIA(-) and PCR(+)/EIA(+) patients, respectively).

231 , that is, PCR-positive/EIA-negative (PCR(+)/EIA(-)) results.

232 Identifying the subgroup of PCR(+)/EIA(-) patients who could have true disease, and therefo

233 A comparison of PCR(+)/EIA(-) patients who received complete treatment to all 1

234 CSF was most highly predictive of a positive EIA result.

235 ith low pretest probabilities had a positive EIA, but four were TC positive.

236 We suggest all positive EIA results be confirmed via culture.

237 th discordant results, that is, PCR-positive/EIA-negative (PCR(+)/EIA(-)) results.

238 in developing country settings, the ProSpecT EIA and PCR for Campylobacter reveal extremely high rate

239 Vista) Histoplasma antigen (Ag) quantitative EIA (MiraVista Diagnostics, Indianapolis, IN).

240 cycles: 69.7%) versus 73 patients receiving EIA alone (>/=5 cycles: 52.1%, P=0.027).

241 ovement to develop a formal legal/regulatory EIA process for large industrial and infrastructure proj

242 ng (MTTT) relies on two different sequential EIAs without the inclusion of an immunoblot.

243 Overall CrAg prevalence by serum EIA was 3.6% (95% CI 2.0-6.0%) for adults with CD4 < 200

244 to replace the standard whole-cell sonicate EIA as a first-tier test for the diagnosis of Lyme disea

245 ult was positive but the whole-cell sonicate EIA result was negative.

246 ed CM patients, compared the LFA to standard EIA and included procalcitonin evaluation.

247 Compared to standard EIA, LFA demonstrates 31% sensitivity (95% CI of 20%-44%

248 g modalities were evaluated, including stool EIA, culture EIA, and real-time PCR (tcdA and tcdB) of c

249 ver, due to the lack of sensitivity of stool EIA, we developed a multiplex real-time PCR assay target

250 The Advia-Centaur CIA and Trep-Sure EIA had signal strength cutoffs correlating with at leas

251 ged from 86.3% (84.1 to 88.2%) for Trep-Sure EIA to 100% for TP-PA (99.6 to 100%).

252 ce interval, 92.3 to 97.3) for the Trep-Sure EIA to 98.4% (96.1 to 99.4) for the Trep-ID EIA.

253 ssay [CIA], Advia-Centaur CIA, and Trep-Sure EIA) and three manual assays (Treponema pallidum particl

254 er recovery of bowel function after IIA than EIA [gas: 2 (IQR 2-3) vs 3 (IQR 2-3) days, P = 0.003; st

255 demonstrate that PCR is more sensitive than EIA and/or culture and distinguishes between O157 and no

256 Our findings demonstrate that EIA can produce sex-specific behavioral effects and immu

257 ns evidence-based, our results indicate that EIA mitigation strategies used to date have been ineffec

258 Molecular studies revealed that EIA also produced prominent sex-specific changes in infl

259 Given that EIAs are undertaken globally, are extremely expensive, a

260 The EIA missed 18.4% detected by the LA assay in the blood s

261 IA (27 stenoses, one dissection), 185 in the EIA (17 thromboses, 167 stenoses, one dissection), one i

262 Here we present the observation of the EIA analog due to constructive interference in a vertica

263 Analysis of the EIA and EPA data indicated that cooling systems operated

264 mproved sensitivity of the LA assay over the EIA in non-HIV patients.

265 ults, we consider the LMNX, similarly to the EIA, useful for HPV-based cervical cancer screening.

266 l platelet activation assays even when their EIAs remain strongly positive.

267 conducted to assess the performance of these EIAs as first-tier tests and when used in two-tiered alg

268 res one of the most commonly used first-tier EIAs in the United States, the combined IgM/IgG Vidas te

269 genic culture, clinical diagnosis, and toxin EIA showed the best fitness.

270 tested by glutamate dehydrogenase and toxin EIA; if discordant results, specimens were reflexed to N

271 ed stool samples tested with a GDH-and-toxin EIA (C.

272 testing algorithm utilizing a GDH-and-toxin EIA and CCNA.

273 ith severe CDI, 58% tested positive by toxin EIA and 98% tested positive by NAAT.

274 with mild CDI, 49% tested positive by toxin EIA and 98% tested positive by NAAT.

275 n for CDI were tested prospectively by toxin EIA, by C. difficile NAAT, and with a reference standard

276 ability using four variables including toxin EIA, toxigenic culture, clinical diagnosis, and fecal ca

277 or died within 90 days after the index toxin EIA date.

278 hod and a Shiga toxin EIA, but a Shiga toxin EIA should not be considered to be an adequate stand-alo

279 se of an agar-based method and a Shiga toxin EIA, but a Shiga toxin EIA should not be considered to b

280 These data demonstrate that toxin EIA performs poorly both for patients with severe CDI an

281 The toxin EIA had 59.8% positive agreement with CCCNA.

282 that the analytical sensitivity of the toxin EIA is poor, there are limited clinical data on the perf

283 The toxin EIA was positive in 37.2% and 35.6% of patients were of

284 ghlights the poor performance of stool toxin EIAs in pediatric settings.

285 s of 97% and 98 to 99% resulted when the two EIA strategies were followed by Western immunoblotting a

286 We assessed diagnostic accuracy using EIA as the gold-standard, and performed additional valid

287 ukotriene and ECP levels were measured using EIAs or ELISAs.

288 operative time was comparable in IIA versus EIA group {130 [interquartile range (IQR) 105-195] vs 13

289 te (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a VlsE chemiluminescence immunoassay (CL

290 We compared CTTT (WCS EIA followed by supplemental immunoblot) to MTTT (WCS EI

291 wed by supplemental immunoblot) to MTTT (WCS EIA followed by C6 EIA) using McNemar's test to evaluate

292 ols included (1) a whole-cell sonicate (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a Vl

293 Here we assess how well EIAs of wind-farm developments protect bats.

294 les from nine were TC positive and four were EIA positive.

295 ng the outcomes of LRC with IIA and LRC with EIA in patients with a benign or malignant right-sided c

296 f postoperative bowel function than LRC with EIA; however, it does not reflect into a shorter LOS.

297 geminal ganglial neurons was quantified with EIA.

298 mpylobacter species revealed reactivity with EIA.

299 Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin)+RHT (>/=5 cycle

300 ses diarrhoea attributable to rotavirus with EIAs or polyacrylamide gel electrophoresis.